Table 2 Potential telomere length modulators in tumor prevention
NO | Compounds | Level | Preclinical Model | Mechanism | Efficacy/Progress |
|---|---|---|---|---|---|
1 | TA65 | Preclinical | Multiple cells | a. Extended the average telomere length of leukocytes b. Increased cytotoxic T cells | Help the body to reinforce the immune system. |
2 | CAG | Preclinical | Multiple cells | a. accelerates the presentation of tumor antigens b. The combination of CAG and PD-1 antibody can also effectively enhance the killing ability of CD8+T cells | Anti-cancer |
3 | Vc | Preclinical | Multiple cancer cells | a. Reduce telomerase activity in HeLa cells by restoring cell redox potential, inhibiting E6 gene and promoting p53 gene expression b. Target redox imbalances, epigenetic reprogramming, and oxygen-sensing regulation in cancer cells | a. Activate telomerase in HeLa cells b. Treat and prevent cancer |